Protein-bound paclitaxel
Encyclopedia
Protein-bound paclitaxel is an injectable formulation of paclitaxel
, a mitotic inhibitor
drug
used in the treatment of breast cancer
. In this formulation, paclitaxel is bonded to albumin
as a delivery vehicle. It is sold in the United States
under the trade name Abraxane by Abraxis Bioscience.
This treatment was approved by the Food and Drug Administration
in January 2005 for breast cancer
cases where cancer did not respond to other chemotherapy
or has relapsed.
Abraxane is a first in its class of drugs using nanoparticle albumin bound (nab) technology platform.
In June 2010, positive results were published from a phase III trial in first-line non-small-cell lung cancer (NSCLC) when compared with Taxol (solvent-based paclitaxel).
Total revenue from the sales of Abraxane for 2009 were $314.5 million.
In 2010, Abraxis was acquired by Celgene, who now market Abraxane.
Paclitaxel
Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a U.S. National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol...
, a mitotic inhibitor
Mitotic inhibitor
A mitotic inhibitor is a drug that inhibits mitosis, or cell division. These drugs disrupt microtubules, which are structures that pull the cell apart when it divides...
drug
Medication
A pharmaceutical drug, also referred to as medicine, medication or medicament, can be loosely defined as any chemical substance intended for use in the medical diagnosis, cure, treatment, or prevention of disease.- Classification :...
used in the treatment of breast cancer
Breast cancer
Breast cancer is cancer originating from breast tissue, most commonly from the inner lining of milk ducts or the lobules that supply the ducts with milk. Cancers originating from ducts are known as ductal carcinomas; those originating from lobules are known as lobular carcinomas...
. In this formulation, paclitaxel is bonded to albumin
Albumin
Albumin refers generally to any protein that is water soluble, which is moderately soluble in concentrated salt solutions, and experiences heat denaturation. They are commonly found in blood plasma, and are unique to other blood proteins in that they are not glycosylated...
as a delivery vehicle. It is sold in the United States
United States
The United States of America is a federal constitutional republic comprising fifty states and a federal district...
under the trade name Abraxane by Abraxis Bioscience.
This treatment was approved by the Food and Drug Administration
Food and Drug Administration
The Food and Drug Administration is an agency of the United States Department of Health and Human Services, one of the United States federal executive departments...
in January 2005 for breast cancer
Breast cancer
Breast cancer is cancer originating from breast tissue, most commonly from the inner lining of milk ducts or the lobules that supply the ducts with milk. Cancers originating from ducts are known as ductal carcinomas; those originating from lobules are known as lobular carcinomas...
cases where cancer did not respond to other chemotherapy
Chemotherapy
Chemotherapy is the treatment of cancer with an antineoplastic drug or with a combination of such drugs into a standardized treatment regimen....
or has relapsed.
Abraxane is a first in its class of drugs using nanoparticle albumin bound (nab) technology platform.
In June 2010, positive results were published from a phase III trial in first-line non-small-cell lung cancer (NSCLC) when compared with Taxol (solvent-based paclitaxel).
Total revenue from the sales of Abraxane for 2009 were $314.5 million.
In 2010, Abraxis was acquired by Celgene, who now market Abraxane.